Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Work In Process (2024 - 2025)

BeOne Medicines (BEIGF) has disclosed Work In Process for 2 consecutive years, with $122.7 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 104.07% to $122.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.7 million through Dec 2025, up 104.07% year-over-year, with the annual reading at $122.7 million for FY2025, 104.07% up from the prior year.
  • Work In Process for Q4 2025 was $122.7 million at BeOne Medicines, up from $60.1 million in the prior quarter.
  • The five-year high for Work In Process was $122.7 million in Q4 2025, with the low at $60.1 million in Q4 2024.